AC Immune
Kemal Arda Gunay is a Vaccine Manufacturing Technology Lead at AC Immune and has extensive experience in research and development through various academic and industry roles. Gunay completed a Ph.D. in Materials Science and Engineering at École polytechnique fédérale de Lausanne (EPFL), following a Master’s Degree in the same field at EPFL. Previous positions include Postdoctoral Researcher and Fellow at the University of Colorado Boulder and Howard Hughes Medical Institute, respectively, as well as a Research Intern at Firmenich. Kemal Gunay's background combines expertise in polymer chemistry with a focus on vaccine manufacturing technologies.
This person is not in the org chart
This person is not in any teams
AC Immune
3 followers
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.